Category: US Department of Health

Source: US Department of Health and Human Services – 2

News Release

Friday, October 13, 2023

NIH study suggests a small reduction in daily calories is beneficial for wellness.

Reducing overall calorie intake may rejuvenate your muscles and activate biological pathways important for good health, according to researchers at the National Institutes of Health and their colleagues. Decreasing calories without depriving the body of essential vitamins and minerals, known as calorie restriction, has long been known to delay the progression of age-related diseases in animal models. This new study, published in Aging Cell, suggests the same biological mechanisms may also apply to humans.

Researchers analyzed data from participants in the Comprehensive Assessment of Long-Term Effects of Reducing Intake of Energy (CALERIE), a study supported by the National Institute on Aging (NIA) that examined whether moderate calorie restriction conveys the same health benefits seen in animal studies. They found that during a two-year span, the goal for participants was to reduce their daily caloric intake by 25%, but the highest the group was able to reach was a 12% reduction. Even so, this slight reduction in calories was enough to activate most of the biological pathways that are important in healthy aging.

“A 12% reduction in calorie intake is very modest,” said corresponding author and NIA Scientific Director Luigi Ferrucci, M.D., Ph.D. “This kind of small reduction in calorie intake is doable and may make a big difference in your health.”

The research team next sought to understand the molecular underpinnings of the benefits seen in limited, previous research of calorie restriction in humans. One study showed that individuals on calorie restriction lost muscle mass and an average of 20 pounds of weight over the first year and maintained their weight for the second year. However, despite losing muscle mass, calorie restriction participants did not lose muscle strength, indicating calorie restriction improved the amount of force generated by each unit of muscle mass, called muscle specific force.

For the current study, scientists used thigh muscle biopsies from CALERIE participants that were collected when individuals joined the study and at one-year and two-year follow ups.

To figure out which human genes were impacted during calorie restriction, the scientists isolated messenger RNA (mRNA), a molecule that contains the code for proteins, from muscle samples. The team determined the protein sequence of each mRNA and used the information to identify which genes originated specific mRNAs. Further analysis helped the scientists establish which genes during calorie restriction were upregulated, meaning the cells made more mRNA; and which were downregulated, meaning the cells produced less mRNA. The researchers confirmed calorie restriction affected the same gene pathways in humans as in mice and non-human primates. For example, a lower caloric intake upregulated genes responsible for energy generation and metabolism, and downregulated inflammatory genes leading to lower inflammation.

“Since inflammation and aging are strongly coupled, calorie restriction represents a powerful approach to preventing the pro-inflammatory state that is developed by many older people,” said Ferrucci.

This research was supported by the NIA Intramural Research Program and the following NIH grants: R01AG061378, P30AG028716, R01AG054840, U01AG060906, R01AG071707, R33AG070455, U01AG020478, U01AG020480, U01AG020487, U01AG022132.

About the National Institute on Aging (NIA): NIA leads the U.S. federal government effort to conduct and support research on aging and the health and well-being of older people. Learn more about age-related cognitive change and neurodegenerative diseases via NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center website. Visit the main NIA website for information about a range of aging topics, in English and Spanish, and stay connected.

About the National Institutes of Health (NIH): NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

NIH…Turning Discovery Into Health^®

###

Source: US Department of Health and Human Services – 2

Media Advisory

Friday, October 13, 2023

NIH-supported research finds key differences between children & adults with COVID-19.

What

New research helps explain why young children have lower rates of severe COVID-19 than adults. A study of infants and young children found those who acquired SARS-CoV-2 had a strong, sustained antibody response to the virus and high levels of inflammatory proteins in the nose but not in the blood. This immune response contrasts with that typically seen in adults with SARS-CoV-2 infection. Co-funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, the research appears in the journal Cell. 

The investigation involved 81 full-term infants and young children whose mothers enrolled in a NIAID-supported cohort study at Cincinnati Children’s during their third trimester of pregnancy. The study team trained mothers to collect weekly nasal swabs from their infants starting when the babies were 2 weeks old. The team also drew blood from the babies regularly, starting at age 6 weeks, as well as when the children became infected with SARS-CoV-2 and during subsequent weeks and months.

These samples enabled the scientists to study the children’s immune responses before, during and after they were exposed to the virus for the first time. Fifty-four of the children became infected and had mild COVID-19, while 27 who tested negative through the study period served as matched controls. At the time of infection, the children were 1 month to nearly 4 years old, and half were 9 months or younger. The study also included weekly nasal swabs from 19 mothers with COVID-19 and 19 healthy mothers as controls, as well as blood samples from 89 adults with COVID-19 and 13 healthy controls.

The researchers examined many aspects of the babies’ and adults’ immune responses to the virus through an approach called systems immunology. The study revealed that young children’s antibody response to SARS-CoV-2 differs from that of adults. Typically, adults produce antibodies to the virus at levels that spike for a few weeks, then decline. In contrast, the infants and young children in the study produced protective antibodies at levels that spiked and remained high for up to the full 300-day observation period.

The scientists also found that the blood of adults with SARS-CoV-2 infection typically had high levels of proteins called inflammatory cytokines, which are associated with severe COVID-19 and death, while the blood of babies and children did not. However, the children’s noses had high levels of inflammatory cytokines and a potent antiviral cytokine.

According to the researchers, these findings suggest that cytokines snuffed out SARS-CoV-2 infection right at the site where the virus entered the children’s bodies, potentially explaining the mildness of their COVID-19 disease. The findings also suggest it may be possible to devise vaccine adjuvants that mimic the immune responses observed in young children by stimulating persistently high antibody levels without causing dangerous excess inflammation in the blood.   

Children aged 6 months to 4 years who got COVID-19 vaccines before September 12, 2023, should get one or two doses of updated COVID-19 vaccine, depending on which vaccine and how many doses they previously received. Children aged 6 months to 4 years who have not been vaccinated should get two or three doses of updated COVID-19 vaccine, depending on which vaccine they receive.

Pali Pulendran, Ph.D., and Mary Allen Staat, M.D., M.P.H., led the study. Dr. Pulendran is the Violetta L. Horton Professor and co-director of the Institute for Immunology, Transplantation and Infection at Stanford University in California. Dr. Staat is the Kulkarni Endowed Chair in Infectious Diseases and a professor of pediatric infectious diseases at Cincinnati Children’s.

Article

F Wimmers et al. Multi-omics analysis of mucosal and systemic immunity to SARS-CoV-2 after birth. Cell DOI: 10.1016/j.cell.2023.08.044 (2023).

Who

Mercy R. Prabhudas, Ph.D., M.B.A., a program officer in the NIAID Division of Allergy, Immunology, and Transplantation, is available to discuss this study.

NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website.

About the National Institutes of Health (NIH): NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

NIH…Turning Discovery Into Health^®

###

Source: US Department of Health and Human Services – 2

News Release

Friday, October 13, 2023

Blood calcium levels normalized in clinical trial participants.

An investigational drug, encaleret, restored calcium levels in people with autosomal dominant hypocalcemia type 1 (ADH1), a rare genetic disorder marked by an imbalance of calcium in the blood and urine, as well as abnormally low levels of parathyroid hormone, which regulates blood calcium levels. Led by clinician-scientists from the National Institute of Dental and Craniofacial Research (NIDCR) at the National Institutes of Health’s Clinical Center, results from the clinical trial are published in the New England Journal of Medicine.

In the mid-phase clinical trial, 13 participants with ADH1 received oral doses of the investigational drug for about 24 weeks. By the end of the trial, the treatment restored every participant’s blood calcium level to normal, and urine calcium approached normal levels. Levels of parathyroid hormone also normalized.

“It was amazing to see that every participant responded to the treatment. In literally minutes after taking the medication orally, the levels of parathyroid hormone increased dramatically,” said senior author and NIDCR endocrinologist Michael Collins, M.D.

Our bodies need calcium for proper functioning of many organs and tissues, including the bones, teeth, heart, muscles, and nerves. However, in people with ADH1, calcium levels in the blood are unusually low, leading to symptoms that can range from tingling limbs, muscle cramps, and brain fog to life-threatening seizures. Between 1.4 and 3.9 in 100,000 people in the U.S. are affected by the disease. While current therapies can help manage symptoms, there are no approved treatments that address the root cause of the condition.

“Conventional therapy is to raise the blood calcium level with calcium supplements and activated vitamin D,” said principal investigator and NIDCR pediatric endocrinologist Rachel Gafni, M.D. “However, too much of an increase could cause kidney stones or damage kidney tissues, leading to kidney failure in worst-case scenarios. The patients need better treatments, so we’re not constantly walking on a tightrope.”

Encaleret is thought to exert its effects by acting on faulty calcium-sensing receptors that are peppered throughout the kidneys and pea-sized organs in the neck called parathyroid glands. In healthy people, these receptors act like thermostats to monitor and control calcium levels. However, in patients with ADH1, the receptors are too sensitive and falsely interpret normal blood calcium levels as high. As a result, the parathyroid glands do not make enough parathyroid hormone and the kidneys flush too much calcium out of the body. This leads to low calcium levels in the blood and high levels in the urine.

“This clinical trial, which was made possible by a public-private partnership, really demonstrates the value of collaboration and the institute’s commitment and success in translating research into health,” said NIDCR Director Rena D’Souza, D.D.S., Ph.D.

Encaleret appeared to be safe and caused no serious side effects. However, because parathyroid hormone raises blood calcium levels in part by drawing calcium from the bones, the researchers noted a need to assess the treatment’s long-term effects on the skeleton. The researchers also speculate encaleret may have broader implications. An ongoing clinical trial led by Dr. Collins and NIDCR staff clinician Iris Hartley, M.D., is testing whether the treatment can help correct calcium levels in people whose parathyroid glands have been damaged by surgery.

“Because ADH1 can be passed on to offspring, the participants are not just doing this for themselves; it’s for their children, grandchildren, and great-grandchildren,” said Dr. Gafni. “One day, hopefully, we’ll be writing prescriptions for an effective treatment thanks to them.”

This research was supported by a public-private partnership between the NIDCR Division of Intramural Research and BridgeBio Pharma Inc. affiliate Calcilytix Therapeutics, Inc., under a Cooperative Research and Development Agreement.

About the National Institute of Dental and Craniofacial Research: NIDCR is the nation’s leading funder of research on oral, dental, and craniofacial health.

About the National Institutes of Health (NIH): NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

NIH…Turning Discovery Into Health^®

###

Source: US Department of Health and Human Services – 2

News Release

Thursday, October 12, 2023

Incredibly detailed cell maps help pave the way for new generation of treatments.

A group of international scientists have mapped the genetic, cellular, and structural makeup of the human brain and the nonhuman primate brain. This understanding of brain structure, achieved by funding through the National Institutes of Health’s Brain Research Through Advancing Innovative Neurotechnologies® Initiative, or The BRAIN Initiative®, allows for a deeper knowledge of the cellular basis of brain function and dysfunction, helping pave the way for a new generation of precision therapeutics for people with mental disorders and other disorders of the brain. The findings appear in a compendium of 24 papers across Science, Science Advances, and Science Translational Medicine.

“Mapping the brain’s cellular landscape is a critical step toward understanding how this vital organ works in health and disease,” said Joshua A. Gordon, M.D., Ph.D., director of the National Institute of Mental Health. “These new detailed cell atlases of the human brain and the nonhuman primate brain offer a foundation for designing new therapies that can target the specific brain cells and circuits involved in brain disorders.” 

The 24 papers in this latest BRAIN Initiative Cell Census Network (BICCN) collection detail the exceptionally complex diversity of cells in the human brain and the nonhuman primate brain. The studies identify similarities and differences in how cells are organized and how genes are regulated in the human brain and the nonhuman primate brain. For example:

• Three papers in the collection present the first atlas of cells in the adult human brain, mapping the transcriptional and epigenomic landscape of the brain. The transcriptome is the complete set of gene readouts in a cell, which contains instructions for making proteins and other cellular products. The epigenome refers to chemical modifications to a cell’s DNA and chromosomes that alter the way the cell’s genetic information is expressed.
• In another paper, a comparison of the cellular and molecular properties of the human brain and several nonhuman primate brains (chimpanzee, gorilla, macaque, and marmoset brains) revealed clear similarities in the types, proportions, and spatial organization of cells in the cerebral cortex of humans and nonhuman primates. Examination of the genetic expression of cortical cells across species suggests that relatively small changes in gene expression in the human lineage led to changes in neuronal wiring and synaptic function that likely allowed for greater brain plasticity in humans, supporting the human brain’s ability to adapt, learn, and change.
• A study exploring how cells vary in different brain regions in marmosets found a link between the properties of cells in the adult brain and the properties of those cells during development. The link suggests that developmental programming is embedded in cells when they are formed and maintained into adulthood and that some observable cellular properties in an adult may have their origins very early in life. This finding could lead to new insights into brain development and function across the lifespan.
• An exploration of the anatomy and physiology of neurons in the outermost layer of the neocortex—part of the brain involved in higher-order functions such as cognition, motor commands, and language—revealed differences in the human brain and the mouse brain that suggest this region may be an evolutionary hotspot, with changes in humans reflecting the higher demands of regulating humans’ more complex brain circuits.

The core aim of the BICCN, a groundbreaking effort to understand the brain’s cellular makeup, is to develop a comprehensive inventory of the cells in the brain—where they are, how they develop, how they work together, and how they regulate their activity—to better understand how brain disorders develop, progress, and are best treated.

“This suite of studies represents a landmark achievement in illuminating the complexity of the human brain at the cellular level,” said John Ngai, Ph.D., director of the NIH BRAIN Initiative. “The scientific collaborations forged through BICCN are propelling the field forward at an exponential pace; the progress—and possibilities—have been simply breathtaking.”

The census of brain cell types in the human brain and the nonhuman primate brain presented in this paper collection serves as a key step toward developing the brain treatments of the future. The findings also set the stage for the BRAIN Initiative Cell Atlas Network, a transformative project that, together with two other large-scale projects—the BRAIN Initiative Connectivity Across Scales and the Armamentarium for Precision Brain Cell Access—aim to revolutionize neuroscience research by illuminating foundational principles governing the circuit basis of behavior and informing new approaches to treating human brain disorders.

Grants: Projects funded through the NIH BRAIN Initiative Cell Census Network

About the National Institute of Mental Health (NIMH): The mission of the NIMH is to transform the understanding and treatment of mental illnesses through basic and clinical research, paving the way for prevention, recovery, and cure. For more information, visit the NIMH website.

The NIH BRAIN Initiative is managed by 10 Institutes and Centers whose missions and current research portfolios complement the goals of The BRAIN Initiative^®: National Center for Complementary and Integrative Health, National Eye Institute, National Institute on Aging, National Institute on Alcohol Abuse and Alcoholism, National Institute of Biomedical Imaging and Bioengineering, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institute on Drug Abuse, National Institute on Deafness and other Communication Disorders, National Institute of Mental Health, and National Institute of Neurological Disorders and Stroke.

About the National Institutes of Health (NIH): NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

NIH…Turning Discovery Into Health^®

###

Source: US Department of Health and Human Services – 2

Source: US Department of Health and Human Services – 2

News Release

Tuesday, October 10, 2023

NIH-supported research provides broader understanding of how cardiovascular disease risk manifests following pregnancy.

Having obesity before and during early pregnancy appears to be a strong indicator of risk for developing future cardiovascular disease and was significantly linked with adverse outcomes during pregnancy such as high blood pressure, preeclampsia, and gestational diabetes, according to a study published in Circulation Research that was funded by the National Institutes of Health. Researchers have known obesity is a risk factor for cardiovascular disease and pregnancy complications related to blood pressure. However, they did not know which factors – obesity or the pregnancy complications – played larger roles in influencing a person’s cardiovascular disease risk years after pregnancy.

While having adverse pregnancy outcomes was linked with increased cardiovascular disease risks during pregnancy, the complications accounted for a small percentage of increased cardiovascular disease risks in the years following pregnancy for people with obesity.

“We’re finding that certain pregnancy complications are unmasking and then increasing cardiovascular disease risks, such as obesity, that were already present. This study provides insight into potential timing for interventions for people with overweight or obesity who are thinking about pregnancy,” said Victoria L. Pemberton, R.N.C., a study author and researcher in the Division of Cardiovascular Sciences at the National Heart, Lung, and Blood Institute (NHLBI), part of NIH.

The researchers analyzed data collected from the nuMoM2b Heart Health Study of more than 4,200 first-time mothers – about half of whom had overweight or obesity. They compared the participants’ pregnancy experience to their health two to seven years later. They found mothers who were overweight or had obesity during the first trimester of pregnancy had about twice the risk for developing gestational diabetes or having a pregnancy complicated by high blood pressure, compared to participants with a normal body weight. These mothers also had increased risks for developing cardiovascular disease risks after pregnancy.

In comparison, pregnancies complicated by high blood pressure explained just 13% of future risks for developing high blood pressure if a person had obesity. Likewise, gestational diabetes explained only 10% of future risks for diabetes.

“We want to do everything we can to support a person’s heart health, but especially around the time of pregnancy – before, during, and in early pregnancy,” said Sadiya S. Khan, M.D., the study’s lead investigator, a preventive cardiologist, and an associate professor of medicine at Northwestern University Feinberg School of Medicine, Chicago. “That includes achieving and maintaining a healthy body weight, knowing your heart health numbers, and finding ways to stay physically active.”

For some complications the researchers found body weight did not factor into risks. For example, people with overweight or obesity did not have increased risks for having a preterm birth or a baby with a low birthweight. Additionally, researchers found among all participants, those experiencing preterm births had increased risks for having high blood pressure, high blood sugar, or high cholesterol a few years after pregnancy. Having a baby born with a low birthweight wasn’t found to increase risks.

“Looking for ways to support and optimize a person’s cardiovascular health is still of the utmost importance if someone has had an adverse pregnancy outcome,” said Khan. “However, if we really want to make a difference in improving cardiovascular health and preventing these pregnancy outcomes, we have to shift to the pre-pregnancy and early pregnancy space.”

To learn about heart health and pregnancy, visit https://www.nhlbi.nih.gov/health-topics/education-and-awareness/heart-truth/listen-to-your-heart/heart-health-and-pregnancy.

This research was supported by NHLBI grant R01 HL161514. The Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Center for Advancing Translational Sciences, Office of Research on Women’s Health, and the Office of Disease Prevention provided additional support.         

About the National Heart, Lung, and Blood Institute (NHLBI): NHLBI is the global leader in conducting and supporting research in heart, lung, and blood diseases and sleep disorders that advances scientific knowledge, improves public health, and saves lives. For more information, visit https://www.nhlbi.nih.gov/.

About the National Institutes of Health (NIH): NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

NIH…Turning Discovery Into Health^®

###

Source: US Department of Health and Human Services – 2

Source: US Department of Health and Human Services – 2

Source: US Department of Health and Human Services – 2

News Release

Thursday, September 28, 2023

NIH-funded research sheds light on link between COVID-19 infection and increased risk of cardiovascular disease and stroke.

SARS-CoV-2, the virus that causes COVID-19, can directly infect the arteries of the heart and cause the fatty plaque inside arteries to become highly inflamed, increasing the risk of heart attack and stroke, according to a study funded by the National Institutes of Health. The findings, published in the journal Nature Cardiovascular Research, may help explain why certain people who get COVID-19 have a greater chance of developing cardiovascular disease, or if they already have it, develop more heart-related complications.

In the study, researchers focused on older people with fatty buildup, known as atherosclerotic plaque, who died from COVID-19. However, because the researchers found the virus infects and replicates in the arteries no matter the levels of plaque, the findings could have broader implications for anybody who gets COVID-19.

“Since the early days of the pandemic, we have known that people who had COVID-19 have an increased risk for cardiovascular disease or stroke up to one year after infection,” said Michelle Olive, Ph.D., acting associate director of the Basic and Early Translational Research Program at the National Heart, Lung, and Blood Institute (NHLBI), part of NIH. “We believe we have uncovered one of the reasons why.”

Though previous studies have shown that SARS-CoV-2 can directly infect tissues such as the brain and lungs, less was known about its effect on the coronary arteries. Researchers knew that after the virus reaches the cells, the body’s immune system sends in white blood cells known as macrophages to help clear the virus. In the arteries, macrophages also help remove cholesterol, and when they become overloaded with cholesterol, they morph into a specialized type of cell called foam cells.

The researchers thought that if SARS-CoV-2 could directly infect arterial cells, the macrophages that normally are turned loose might increase inflammation in the existing plaque, explained Chiara Giannarelli, M.D., Ph.D., associate professor in the departments of medicine and pathology at New York University’s Grossman School of Medicine and senior author on the study. To test their theory, Giannarelli and her team took tissue from the coronary arteries and plaque of people who had died from COVID-19 and confirmed the virus was in those tissues. Then they took arterial and plaque cells – including macrophages and foam cells – from healthy patients and infected them with SARS-CoV-2 in a lab dish. They found that the virus had also infected those cells and tissues.

Additionally, the researchers found that when they compared the infection rates of SARS-CoV-2, they showed that the virus infects macrophages at a higher rate than other arterial cells. Cholesterol-laden foam cells were the most susceptible to infection and unable to readily clear the virus. This suggested that foam cells might act as a reservoir of SARS-CoV-2 in the atherosclerotic plaque. Having more build-up of plaque, and thus a greater number of foam cells, could increase the severity or persistence of COVID-19.

The researchers then turned their attention to the inflammation they predicted might occur in the plaque after infecting it with the virus. They quickly documented the release of molecules, known as cytokines, that are known to increase inflammation and promote the formation of even more plaque. The cytokines were released by infected macrophages and foam cells. The researchers said this may help explain why people who have underlying plaque buildup and then get COVID-19 may have cardiovascular complications long after getting the infection.  

“This study is incredibly important as it adds to the larger body of work to better understand COVID-19,” said Olive. “This is just one more study that demonstrates how the virus both infects and causes inflammation in many cells and tissues throughout the body. Ultimately, this is information that will inform future research on both acute and Long COVID.”

Though the findings conclusively show that SARS-CoV-2 can infect and replicate in the macrophages of plaques and arterial cells, they are only relevant to the original strains of SARS-CoV-2 that circulated in New York City between May 2020 and May 2021. The study was conducted in a small cohort of older individuals, all of whom had atherosclerosis and other medical conditions; therefore, the results cannot be generalized to younger, healthy individuals.

This work was funded by the NIH/NHLBI grants 1R01HL165258, R01HL153712, R35HL135799 and R01HL084312. NIAID and NIDDK also provided funding.

About the National Heart, Lung, and Blood Institute (NHLBI): NHLBI is the global leader in conducting and supporting research in heart, lung, and blood diseases and sleep disorders that advances scientific knowledge, improves public health, and saves lives. For more information, visit www.nhlbi.nih.gov.

About the National Institutes of Health (NIH): NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

NIH…Turning Discovery Into Health^®

###

Source: US Department of Health and Human Services – 2

News Release

Wednesday, September 27, 2023

Awards to community organizations will enable examination of structural drivers of health.

The National Institutes of Health is funding a first-of-its-kind community-led research program to study ways to address the underlying structural factors within communities that affect health, such as access to safe spaces, healthy food, employment opportunities, transportation, and quality health care. Through the NIH Common Fund Community Partnerships to Advance Science for Society (ComPASS) program, NIH made 26 awards to community organizations and a coordinating center, totaling approximately $171 million over five years, pending the availability of funds. Through these awards, ComPASS will enable research into sustainable solutions that promote health equity to create lasting change in communities across the nation.

NIH is directly funding research projects led by community organizations. Leaders from the organizations will work in collaboration with their research partners at academic institutions and other organizations in all phases of the research process. ComPASS projects study social determinants of health — the social, physical, and economic conditions where people are born, grow, live, work, age, and play — that contribute to health inequities.

“The ComPASS research model harnesses diverse perspectives and expertise to examine systemic factors that impact the health of individuals, communities, and populations,” said NIH Acting Director Lawrence Tabak, D.D.S., Ph.D. “We are excited to see how results from these awards exemplify the transformative power of community-driven research.”

The projects will examine underlying conditions and environments that influence health outcomes by enabling the development, implementation, and assessment of structural interventions. Structural interventions are meant to alter social determinants of health by changing factors that create differences in opportunities to achieve optimal health.

Each award will foster the design of strategies to improve health outcomes through innovative structural interventions to address community concerns, such as economic development, social and community context, neighborhood characteristics, health care access and quality, and nutrition and food environment. Community organizations and their research partners will work together to develop a structural intervention, launch it within their communities, and then assess whether the intervention improves health outcomes. Several examples of ComPASS-supported research projects, which focus on populations that experience health disparities, include:

• Supporting access to healthy food in underserved rural communities through the delivery of food boxes to local stores and individuals, and facilitating local food harvesting, processing, and distribution in the community. The project will measure whether these interventions reduce hunger, improve diet quality, promote healthy weight, and protect people against chronic diseases such as diabetes and cardiovascular disease.
• Assessing whether early childcare strategies improve mental health for children and their parents and guardians. This project will develop and examine community strategies that increase access to public early childcare, education, and programming to support young children and families in areas with limited access to childcare.
• Enhancing access to health care through individualized travel information and resources along with a transportation stipend for health care and related trips. The project will assess whether improved transportation access can reduce emergency department readmissions and secondary infections, decrease hospital costs, and improve disease management.
• Improving access to quality health care for older adults from sexual and gender minority populations by creating culturally appropriate and inclusive protocols in the local health system. The project will measure how these changes in the local health system affect overall physical and mental health.
• Assessing whether enhancing telehealth models in rural communities can improve preventative screening and disease management for cancer, depression, diabetes, high blood pressure, and other chronic diseases among agricultural workers. The project will improve telehealth by transforming the workers’ access to affordable, reliable high-speed broadband internet.

NIH will gain valuable experience and insight into how to support successful future community-led health research. Each project will also contribute valuable data to a growing body of knowledge about social determinants of health and structural inequities.  

The ComPASS program is funded by the NIH Common Fund and managed collaboratively by NIH staff from the Common Fund; National Cancer Institute; National Institute of Mental Health; National Institute on Minority Health and Health Disparities; National Institute of Nursing Research; National Heart, Lung, and Blood Institute; and NIH Office of Research on Women’s Health, with many of the NIH Institutes Centers and Offices providing input and participating in program development and management. More information is available on the ComPASS program website: https://commonfund.nih.gov/compass.  

To learn more about ComPASS, watch this brief video: https://www.youtube.com/watch?v=PVQVYQBh6KM

About the NIH Common Fund: The NIH Common Fund encourages collaboration and supports a series of exceptionally high-impact, NIH-wide programs. Common Fund programs are managed by the Office of Strategic Coordination in the Division of Program Coordination, Planning, and Strategic Initiatives in the NIH Office of the Director in partnership with the NIH Institutes, Centers, and Offices.  More information is available at the Common Fund website: https://commonfund.nih.gov.

About the National Institutes of Health (NIH): NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

NIH…Turning Discovery Into Health^®

###